Search

Your search keyword '"Vapiwala, Neha"' showing total 18 results
Start Over Author "Vapiwala, Neha" Journal practical radiation oncology
18 results on '"Vapiwala, Neha"'

5. 18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE

Author

Adler, Lee P., Andriole, Gerald L., Belkoff, Laurence H., Burzon, Daniel, Chau, Albert, Dato, Paul, Duan, Fenghai, Farwell, Michael, Fogelson, Stephen, Gardiner, Peter, Hanna, Lucy, Hoffman, John M., Intenzo, Charles, Josephson, David, Kaminetsky, Jed, Kipper, Michael, Kostakoglu, Lale, Krynyckyi, Borys, Linder, Karen E., Mahmood, Umar, Marques, Helga, Mankoff, David, McConathy, Jonathan, Melnick, John, Miller, Matthew P., Oh, William, Philips, Shaile, Rose, Judith, Savir-Baruch, Bital, Schuster, David M., Siegel, Barry A., Stevens, Daniel J., Tewari, Ashutosh, Twardowski, Przemyslaw, Ward, Penelope, Wasserman, Martha, Weick, Sharon, (Michael) Yu, Jian Q., Solanki, Abhishek A., Liauw, Stanley L., Michalski, Jeff, Tward, Jonathan D., Vapiwala, Neha, and Teoh, Eugene J.

Published
2020
Full Text
View/download PDF

15. 18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE

Author

Solanki, Abhishek A., primary, Savir-Baruch, Bital, additional, Liauw, Stanley L., additional, Michalski, Jeff, additional, Tward, Jonathan D., additional, Vapiwala, Neha, additional, Teoh, Eugene J., additional, Adler, Lee P., additional, Andriole, Gerald L., additional, Belkoff, Laurence H., additional, Burzon, Daniel, additional, Chau, Albert, additional, Dato, Paul, additional, Duan, Fenghai, additional, Farwell, Michael, additional, Fogelson, Stephen, additional, Gardiner, Peter, additional, Hanna, Lucy, additional, Hoffman, John M., additional, Intenzo, Charles, additional, Josephson, David, additional, Kaminetsky, Jed, additional, Kipper, Michael, additional, Kostakoglu, Lale, additional, Krynyckyi, Borys, additional, Linder, Karen E., additional, Mahmood, Umar, additional, Marques, Helga, additional, Mankoff, David, additional, McConathy, Jonathan, additional, Melnick, John, additional, Miller, Matthew P., additional, Oh, William, additional, Philips, Shaile, additional, Rose, Judith, additional, Schuster, David M., additional, Siegel, Barry A., additional, Stevens, Daniel J., additional, Tewari, Ashutosh, additional, Twardowski, Przemyslaw, additional, Ward, Penelope, additional, Wasserman, Martha, additional, Weick, Sharon, additional, and (Michael) Yu, Jian Q., additional

Published
2020
Full Text
View/download PDF

18. 18 F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE.

Author

Solanki AA, Savir-Baruch B, Liauw SL, Michalski J, Tward JD, Vapiwala N, and Teoh EJ

Subjects
Humans, Male, Neoplasm Recurrence, Local diagnostic imaging, Neoplasm Recurrence, Local radiotherapy, Prospective Studies, Prostate-Specific Antigen, Prostatectomy, Positron Emission Tomography Computed Tomography, Prostatic Neoplasms diagnostic imaging, Prostatic Neoplasms radiotherapy, Prostatic Neoplasms surgery, Salvage Therapy
Abstract

Purpose: Conventional imaging rarely localizes the site(s) of prostate cancer recurrence in patients undergoing evaluation for salvage radiation therapy (sRT) after radical prostatectomy (RP). LOCATE (NCT02680041) was a prospective, multicenter study investigating the impact of 18 F-fluciclovine positron emission tomography and computed tomography (PET/CT) on the management of patients with biochemical recurrence of prostate cancer after curative-intent radiation or RP and negative or equivocal conventional imaging. Our objective was to determine the impact of 18 F-fluciclovine PET/CT on treatment decisions for men planning to undergo sRT for biochemical recurrence post-RP., Methods and Materials: We conducted a subgroup analysis of post-RP patients enrolled in LOCATE who were planning to undergo sRT with or without hormonal therapy based on prescan documentation. 18 F-Fluciclovine PET/CT was performed according to standardized procedures. The treatment plan postscan was compared with the prescan plan, and Fisher exact test was used to determine the impact of prescan prostate-specific antigen (PSA) and Gleason sum (GS) on positivity and anatomic patterns of uptake., Results: A total of 114 patients (median prescan PSA 0.42 [interquartile range, 0.3-1.1] ng/mL) met selection criteria (54% of patients in LOCATE). Forty-eight (42%) had 18 F-fluciclovine-avid lesions. Twelve patients (11%) had positive findings only in the prostate bed, 24 (21%) had positivity only in the pelvis (prostate bed or pelvic nodes), and 24 (21%) had extrapelvic findings. PSA >0.5 ng/mL and GS ≥8 were associated with a higher risk of extrapelvic positivity (P < .05). Postscan, 55 (48%) patients had a management change; 37 (32%) had a change in overall treatment approach (ie, omission of sRT); and 18 (16%) had sRT target modification., Conclusions: 18 F-Fluciclovine PET/CT is positive in nearly half of patients planning to undergo post-RP sRT with negative/equivocal conventional imaging, with findings frequently leading to changes in management. PSA >0.5 ng/mL and GS ≥8 are associated with a higher risk of extrapelvic positive findings., (Published by Elsevier Inc.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results